These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 27667784

  • 1. Treatment of eosinophilic otitis media with pegylated interferon-α 2a and 2b.
    Neff BA, Voss SG, Carlson ML, O'Brien EK, Butterfield JH.
    Laryngoscope; 2017 May; 127(5):1208-1216. PubMed ID: 27667784
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM, Ahmed A, Mahmoud S, Nabegh L, El Gohary I, Obadan I, Hafez T, Ghoraba D, Aziz AA, Metaoei M.
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [Abstract] [Full Text] [Related]

  • 4. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
    Dogan UB, Golge N, Akin MS.
    Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1312-6. PubMed ID: 23652913
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma.
    Hüsken AC, Tsianakas A, Hensen P, Nashan D, Loquai C, Beissert S, Luger TA, Sunderkötter C, Schiller M.
    J Eur Acad Dermatol Venereol; 2012 Jan; 26(1):71-8. PubMed ID: 22168776
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the Safety Profiles of Pegylated Interferon α-2a and α-2b Administered in Combination with Ribavirin for Chronic Hepatitis C Infection: A Real-World Retrospective Cohort Study.
    Ide K, Sato I, Imai T, Hawke P, Yamada H, Kawasaki Y, Masaki N.
    Biol Pharm Bull; 2016 Dec 01; 39(12):2060-2065. PubMed ID: 27645378
    [Abstract] [Full Text] [Related]

  • 8. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A, Rodríguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM.
    J Gastroenterol Hepatol; 2008 Jun 01; 23(6):861-6. PubMed ID: 18422960
    [Abstract] [Full Text] [Related]

  • 9. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
    Halfon P, Pérusat S, Bourlière M, Bronowicki JP, Trimoulet P, Benhamou Y, Leroy V, Marcellin P, Foucher J, Penaranda G, Chêne G, Couzigou P, ANRS HC16 GAMMATRI Study Group.
    J Med Virol; 2010 Dec 01; 82(12):2027-31. PubMed ID: 20981789
    [Abstract] [Full Text] [Related]

  • 10. Use of IL-5 Inhibitor Benralizumab as a Novel Therapy for Eosinophilic Otitis Media: Clinical Capsule and Review of Literature.
    Chow K, Cosetti MK.
    Otol Neurotol; 2020 Feb 01; 41(2):e238-e240. PubMed ID: 31923159
    [Abstract] [Full Text] [Related]

  • 11. Successful treatment of eosinophilic otitis media associated with severe bronchial asthma with an anti-IL-5 monoclonal antibody, mepolizumab.
    Suzaki I, Kimura Y, Tanaka A, Hirano K, Ishibashi A, Mizuyoshi T, Ando I, Kitajima T, Watanabe S, Hinohira Y, Kobayashi H.
    Auris Nasus Larynx; 2019 Feb 01; 46(1):141-146. PubMed ID: 29909018
    [Abstract] [Full Text] [Related]

  • 12. Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media.
    Iino Y, Hara M, Hasegawa M, Matsuzawa S, Shinnabe A, Kanazawa H, Yoshida N.
    Acta Otolaryngol; 2014 Apr 01; 134(4):366-72. PubMed ID: 24628335
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long-Term Efficacy of Pegylated Interferon Alpha-2b in Behçet's Uveitis: A Small Case Series.
    Celiker H, Kazokoglu H, Direskeneli H.
    Ocul Immunol Inflamm; 2019 Apr 01; 27(1):15-22. PubMed ID: 28700247
    [Abstract] [Full Text] [Related]

  • 16. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis.
    Sporea I, Danila M, Sirli R, Popescu A, Laza A, Baditoiu L.
    J Gastrointestin Liver Dis; 2006 Jun 01; 15(2):125-30. PubMed ID: 16802006
    [Abstract] [Full Text] [Related]

  • 17. [Pegylated interferon alpha 2a in treating chronic hepatitis B patients].
    Tian YL, Zhao W, Shen L, Liu W, Chang JB, Fang ZX, Yin WW, Wang L, Sun XB, Yang YJ.
    Zhonghua Gan Zang Bing Za Zhi; 2006 Nov 01; 14(11):806-10. PubMed ID: 17125604
    [Abstract] [Full Text] [Related]

  • 18. Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study.
    Scotto G, Fazio V, Fornabaio C, Tartaglia A, Di Tullio R, Saracino A, Angarano G.
    J Interferon Cytokine Res; 2008 Oct 01; 28(10):623-9. PubMed ID: 18778199
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effectiveness of instillation of triamcinolone acetonide into the middle ear for eosinophilic otitis media associated with bronchial asthma.
    Iino Y, Nagamine H, Kakizaki K, Komiya T, Katano H, Saruya S, Kodera K.
    Ann Allergy Asthma Immunol; 2006 Dec 01; 97(6):761-6. PubMed ID: 17201235
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.